Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:19 pm Sale | 2024-09-30 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Citadel Advisors LLC | 1,158,219 4.200% | -442,549 (-27.65%) | Filing History |
| 2024-02-14 6:18 pm Purchase | 2023-12-31 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Citadel Advisors LLC | 1,600,768 5.800% | 6,832 (+0.43%) | Filing History |
| 2024-02-14 4:51 pm Purchase | 2023-12-31 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Nantahala Capital Management, LLC | 2,797,588 9.900% | 2,797,588 (New Position) | Filing History |
| 2024-02-14 4:39 pm Unchanged | 2023-12-31 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Great Point Partners, LLC | 2,792,927 9.990% | 0 (Unchanged) | Filing History |
| 2024-02-14 08:56 am Sale | 2023-12-31 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Point72 Asset Management, L.P. | 822,334 3.000% | -743,495 (-47.48%) | Filing History |
| 2024-02-13 5:17 pm Purchase | 2023-12-29 | 13G | VISTAGEN THERAPEUTICS INC VTGN | VANGUARD GROUP INC | 1,834,512 6.790% | 1,834,512 (New Position) | Filing History |
| 2024-02-12 6:27 pm Purchase | 2023-12-31 | 13G | VISTAGEN THERAPEUTICS INC VTGN | STEMPOINT CAPITAL LP | 1,790,182 6.500% | 1,790,182 (New Position) | Filing History |
| 2023-10-16 4:37 pm Purchase | 2023-10-04 | 13G | VISTAGEN THERAPEUTICS INC VTGN | TCG Crossover GP II, LLC | 2,702,157 9.900% | 2,702,157 (New Position) | Filing History |
| 2023-10-16 4:34 pm Purchase | 2023-10-04 | 13G | VISTAGEN THERAPEUTICS INC VTGN | BIOTECHNOLOGY VALUE FUND L P | 2,777,245 9.990% | 2,777,245 (New Position) | Filing History |
| 2023-10-16 4:01 pm Purchase | 2023-10-04 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Citadel Advisors LLC | 1,593,936 5.700% | 1,593,936 (New Position) | Filing History |
| 2023-10-12 4:04 pm Purchase | 2023-10-02 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Great Point Partners, LLC | 2,792,927 9.990% | 2,792,927 (New Position) | Filing History |
| 2023-10-06 4:05 pm Purchase | 2023-10-04 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Commodore Capital LP | 2,367,884 9.900% | 792,884 (+50.34%) | Filing History |
| 2023-10-05 4:47 pm Purchase | 2023-10-04 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Point72 Asset Management, L.P. | 1,565,829 5.600% | 1,565,829 (New Position) | Filing History |
| 2023-08-09 4:15 pm Purchase | 2023-08-07 | 13G | VISTAGEN THERAPEUTICS INC VTGN | Commodore Capital LP | 1,575,000 19.700% | 1,575,000 (New Position) | Filing History |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | BlackRock, Inc. BLK | 0 0.000% | -408,932 (Position Closed) | Filing History |
| 2023-02-14 5:20 pm Sale | 2022-12-31 | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | ORBIMED ADVISORS LLC | 0 0.000% | -350,641 (Position Closed) | Filing History |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | Commodore Capital LP | 0 0.000% | -348,530 (Position Closed) | Filing History |
| 2023-02-14 3:32 pm Sale | 2022-12-31 | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | ACUTA CAPITAL PARTNERS, LLC | 0 0.000% | -391,209 (Position Closed) | Filing History |
| 2023-02-01 4:54 pm Purchase | 2022-12-31 | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | BlackRock, Inc. BLK | 408,932 5.900% | 12,459 (+3.14%) | Filing History |
| 2023-02-01 1:49 pm Sale | 2022-12-31 | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | FRANKLIN RESOURCES INC BEN | 0 0.000% | -337,267 (Position Closed) | Filing History |